Summary - A new market study, titled “Carcinoid Syndrome Management Market Research Report- Global Forecast To 2022 ” has been featured on WiseGuyReports.
Report Description
This report analyzes the global carcinoid syndrome management market by organs affected (small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others) by treatment (chemotherapy, biological therapy, and hepatic artery embolization agents), by end users (hospital, clinics, cancer institute and treatment centers); it also studies the top manufacturers in the market
The major players in global carcinoid syndrome management market include:
- Novartis International AG (Sandoz) (Switzerland)
• Pharmascience Inc. (Canada)
• Omega Laboratories Ltd. (Canada)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Mylan N.V. (USA)
• Ipsen Biopharmaceuticals, Inc. (US)
• Sirtex Medical Limited (Australia)
• BTG International Ltd. (UK)
• Wockhardt Ltd.
• Sun Pharmaceutical Industries Limited (India)
The market revenue and share have been analyzed with respect to the following regions and countries:
Americas
North America
U.S.
Canada
Europe
U.K.
France
Germany
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Middle East & Africa
On the basis of organs affected, the global carcinoid syndrome management market has been categorized into the following segments:
- Small Intestine
• Lungs
• Rectum
• Appendix
• Colon
• Stomach
• Pancreas
• Liver
• Others
On the basis of treatment, the global carcinoid syndrome management market has been categorized into the following segments:
- Chemotherapy
• Biological therapy
• Hepatic Artery Embolization Agents
On the basis of end-users, the global carcinoid syndrome management market has been categorized into the following segments:
- Hospital
• Clinics
• Cancer Institute
• Treatment centers
Research Methodology
Market Research Future analysis is conducted by industry experts who offer insight into industry structure, market segmentation, technology assessment, competitive landscape (CL), and market penetration, as well as on emerging trends. Besides primary interviews (~80%) and secondary research (~20%), their analysis is based on years of professional expertise in their respective industries. Our analysts also predict where the market will be headed in the next five to 10 years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories in different regions are estimated based on primary and secondary research.
Both the top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent sub-markets. The key players in the market were identified through secondary research, and their market contributions in the respective regions were determined through primary and secondary research. This entire process included the study of the annual and financial reports of the top market players and extensive interviews for key insights with industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to arrive at the final quantitative and qualitative data. This data has been consolidated, and detailed inputs and analysis by Market Research Future added before being presented in this report
FOR MORE DETAILS: https://www.wiseguyreports.com/reports/3496555-carcinoid-syndrome-management-market-research-report-global-forecast-to-2022
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
Ph: +162-825-80070 (US)
Ph: +44 203 500 2763 (UK)
Diarrhea, tachycardia, bronchospasm, shortness of breathing, and flushing are most common symptoms of carcinoid syndrome.Carcinoid crisis during surgery and carcinoid heart diseases are the complications associated with the carcinoid syndromeCarcinoid syndrome diarrhea involves the presence of excess serotonin, which stimulates secretion of colonic mucus, increases the peristalsis, and inhibits absorption in the GI tract which leads to diarrheaAre you a Start-up willing to make it big in the Business?
Grab an Exclusive PDF Brochure of Carcinoid Syndrome Diarrhea Treatment Market ReportKey Drivers, Restraints and Opportunities of Carcinoid Syndrome Diarrhea Treatment MarketIncrease in prevalence of carcinoid syndrome is anticipated to drive the carcinoid syndrome diarrhea treatment market.
For instance, according to an article published in Clinics, estimated 60% to 80% prevalence of carcinoid syndrome associated diarrhea has been observed among neuroendocrine tumor patients with elevated urinary 5 – HIAA.According to an article published in Biomedical Journal of Scientific & Technical Research (BJSTR), diarrhea accounts for 80% of carcinoid syndromeCurrently used therapies for carcinoid syndrome are systemic chemotherapy, tyrosin kinase inhibitors, somatostatin analogues, interferon, and systemic chemotherapy.
Introduction of new therapies by key industry players for the treatment of carcinoid syndrome diarrhea is likely to fuel the growth of carcinoid syndrome diarrhea treatment market.For instance, in October 2018, Ipsen Biopharmaceuticals Canada Inc. received approval for XERMELOTM from Health CanadaIn February 2018, Health Canada approved Somatuline Autogel for the treatment of carcinoid syndrome offered by Ipsen Biopharmaceuticals Canada Inc.In February 2017, Food and Drug Administration approved Xermelo (telotristat ethyl) with combination of somatostatin analog (SSA) therapy for the treatment of carcinoid syndrome diarrhea in adult patientsIncrease in awareness about life-threatening complications of carcinoid syndrome is likely to propel the growth of market.
For instance, according to an article published in Neoplasia, NETs (neuroendocrine tumors) accounted for 0.5% of all diagnosed malignancies and the rise in incidence of NETs due to improved awareness is approximately 5.86 per 100,000 population per year.Rise in number of people with carcinoid syndrome in developing countries offers significant opportunities in carcinoid syndrome diarrhea treatmentRequest COVID Analysis on Carcinoid Syndrome Diarrhea Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=75165 North America to Hold Major Share of Global Carcinoid Syndrome Diarrhea Treatment MarketNorth America is expected to hold major share of the global carcinoid syndrome diarrhea treatment market, owing to rise in prevalence of carcinoid syndrome.
This is a positive milestone in providing innovative solution for treatment of neuroendocrine tumors.Expanding Operations in Future?
